Glenmark Q4 PAT seen up 11% at Rs 127 cr

Drug manufacturer Glenmark Pharma is expected to report a growth of 11% year-on-year in its profit after tax of Rs 127 crore for the fourth quarter of FY12 (as per IFRS), according to CNBC-TV18.

May 08, 2012 / 12:58 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Drug manufacturer Glenmark Pharma is expected to report a growth of 11% year-on-year in its profit after tax of Rs 127 crore for the fourth quarter of FY12 (as per IFRS), according to CNBC-TV18.

Revenues are seen going up by 26% to Rs 1,000 crore from Rs 795 crore during the same period.

EBITDA is likely to be doubled at Rs 191 crore for the January-March quarter of 2012 as against Rs 89.3 crore in a year ago period.

Operating profit margin is seen improving at 19% versus 11.2%.

Year-on-year growth is likely to be led by US markets and Latin America/ROW + Europe. Indian business will be sluggish sequentially due to inventory rationalisation while margins will be boosted by forex gain.

first published: May 8, 2012 11:57 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347